Editas Medicine (EDIT) Corporate presentation summary

Strategic vision and pipeline progress

• Advancing in vivo gene editing with EDIT-401, targeting significant LDL-C reduction for hyperlipidemia, aiming for early human proof-of-concept data by end of 2026.

• EDIT-401 demonstrated over 90% mean LDL-C reduction in preclinical studies, surpassing current therapies.

• Broader pipeline includes hematopoietic stem cell programs and expansion into additional in vivo gene editing candidates.

• Focus on developing first- or best-in-class therapies for serious diseases using differentiated upregulation strategies.

• Commitment to patient engagement, incorporating diverse perspectives into drug development.

Corporate governance and leadership

• Board features a supermajority of independent directors, with separate Board Chair and CEO roles.

• Two of three board committees are chaired by female directors; 33% of board members are women.

• Board and committee evaluations are conducted annually, with a focus on refreshment and diversity.

• Experienced leadership team with backgrounds in major biotech and pharmaceutical companies.

Executive compensation and human capital

• Executive compensation is performance-based, with a significant equity focus and no guaranteed bonuses or employment terms.

• Compensation strategy is benchmarked annually against industry peers, with clawback policies in place.

• Employee packages include competitive salaries, equity, flexible work, and professional development opportunities.

• Culture committee fosters engagement, learning, and community involvement.